<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-043199</identifier>
<setSpec>0210-0010</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Topiramate or flunarizine in the preventive treatment of migraine. A comparative study of two series of cases</dc:title>
<dc:description xml:lang="en">Introduction. Both flunarizine and, more recently, topiramate have proved to be effective in the prophylaxis of        migraine. Aim. To compare two independent groups of patients with similar clinical and demographic characteristics who were        treated with flunarizine or topiramate as the preferred drug in the prevention of their migraines and to evaluate effectiveness        and safety according to the medication they received. Patients and methods. All the patients reported more than four episodes a        month and/or transformed migraine according to Silberstein&#146;s criteria, and had never received prophylactic treatment. Data        determined: the number and average number of migraines in the previous month and at the fourth month of treatment, and the        rate of respondents. Results. A total of 125 patients were included in each group. No significant differences were found between        the groups as regards mean age or the average number of migraines in the previous month. With both drugs there was a        significant decrease (0.0001) in the mean number of episodes in the fourth month of treatment, but with no significant difference        between them: topiramate (5.88 ± 3.7 to 2.1 ± 2.5) and flunarizine (5.24 ± 3.2 to 2.3 ± 2.7). The mean reduction in the number        of migraines at the fourth month was 58.2 ± 38.2% with topiramate, and 55.4 ± 37.5% with flunarizine. The respondent rate        was 71% with topiramate and 67% with flunarizine. The percentage of dropouts with topiramate (28%) was higher than with        flunarizine (11%) (0.0013). With topiramate 69 patients reported side effects and 53 patients reported them with flunarizine        (0.0427). Conclusions. Both drugs showed a high degree of effectiveness when used as the preferred drug in the preventive        treatment of migraine. Topiramate offered better results as far as effectiveness is concerned, but also more side effects, none of        which were serious</dc:description>
<dc:creator>Gracia-Naya, M</dc:creator>
<dc:creator>Latorre-Jiménez, A. M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción. La flunaricina y recientemente el topiramato        han mostrado su eficacia en la profilaxis de la migraña. Objetivo.        Comparar dos grupos independientes de pacientes con similares características        clínicas y demográficas tratados con flunaricina o topiramato        como primer fármaco en la prevención de sus migrañas y        valorar la eficacia y tolerabilidad según el fármaco recibido. Pacientes        y métodos. Todos los pacientes presentaban más de cuatro crisis        al mes y/o migraña transformada según los criterios de Silberstein y        nunca habían recibido tratamiento profiláctico. Se determinó: número        y media de crisis en el mes previo y al cuarto mes de tratamiento y        tasa de respondedores. Resultados. Se incluyó a 125 pacientes en cada        grupo. No hubo diferencias significativas entre ambos grupos en        edad media y media de crisis en el mes previo. Con ambos fármacos        hubo un descenso significativo (0,0001) de la media de crisis en el        cuarto mes de tratamiento, aunque sin diferencias significativas: topiramato        (5,88 ± 3,7 a 2,1 ± 2,5) y flunaricina (5,24 ± 3,2 a 2,3 ± 2,7).        La reducción media de crisis al cuarto mes fue del 58,2 ± 38,2% con        topiramato y del 55,4 ± 37,5% con flunaricina. La tasa de respondedores        fue del 71% con topiramato y 67% con flunaricina. El porcentaje        de abandonos con topiramato (28%) fue superior que con flunaricina        (11%) (0,0013). Con topiramato 69 pacientes refirieron efectos        adversos y 53 pacientes con flunaricina (0,0427). Conclusiones. Ambos        fármacos mostraron una alta efectividad cuando se usaron como        primer fármaco en el tratamiento preventivo de la migraña. El topiramato        mostró mejores resultados de efectividad, pero más efectos adversos,        aunque ninguno grave</dc:description>
<dc:source>Rev Neurol;41(12): 705-708, dic. 2005. tab, graf</dc:source>
<dc:identifier>ibc-043199</dc:identifier>
<dc:title xml:lang="es">Topiramato o flunaricina en el tratamiento preventivo de la migraña. Estudio comparativo de dos series de casos</dc:title>
<dc:subject>^d5768^s22003</dc:subject>
<dc:subject>^d34281^s22057</dc:subject>
<dc:subject>^d23266^s22020</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d34281^s22032</dc:subject>
<dc:subject>^d934^s22073</dc:subject>
<dc:subject>^d23266^s22073</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d934^s22020</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d22780</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d5768^s22073</dc:subject>
<dc:subject>^d5768^s22020</dc:subject>
<dc:type>article</dc:type>
<dc:date>200512</dc:date>
</metadata>
</record>
</ibecs-document>
